Words of wisdom. Re: feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism.
Lue
Tom F
TF
Department of Urology, University of California, San Francisco, San Francisco, CA, USA.
Bella
Anthony J
AJ